The differential pseudorabies virus (PRV) vaccines currently in use in the USA have deletions of the genes coding for the glycoprotein I (gl) and/or glycoprotein X (gpX). The absence of gI and/or gpX allow for the serologic differentiation of vaccinated swine from PRV-infected swine using differential enzyme-linked immunosorbent assays (ELISAs). A newly developed pseudorabies vaccine virus has 4 deletions of the viral genome: the genes coding for gI, gpX, and thymidine kinase and a portion of the repeat region to attenuate the virus. The purpose of this work was to evaluate the diagnostic compatibility of the gI/gpX gene-deleted vaccine with 3 differential vaccines and 3 differential ELISAs currently in use. Pigs vaccinated 3 times with the gI/gpX gene-deleted vaccine remained seronegative on the 3 differential ELISAs tested. Pigs previously vaccinated with either a gI or gpX gene-deleted vaccine and then vaccinated with the gI/gpX gene-deleted vaccine remained seronegative on the respective gI or gpX differential assay.
Pseudorabies is a disease that is economically important to the swine industry. 9 Estimates of the average cost of pseudorabies in an infected farrow-to-finish herd range from $22.60/saw/year to $74.75/sow/year. 3 Depending on age, reproductive status, and immunological status, pigs infected with pseudorabies virus (PRV) may appear clinically normal or show clinical signs ranging from mild respiratory disease to acute death. 7 In breeding animals, the greatest economic loss is due to reproductive failure.
The first PRV vaccine was licensed for use in the USA in 1975. 4 Since 1975, several modified live virus (MLV) and killed virus pseudorabies vaccines have been developed. In the 1980s, technological advances made it possible to manipulate viral genes. 4 This breakthrough resulted in the development of MLV vaccines in which portions of the PRV genome, i.e., the thymidine kinase gene and the inverted repeat regions, were removed to reduce the virulence of the virus. The deletion of other genes was also found to be useful. Removal of one or more of the genes coding for the nonessential but antibody-inducing glycoproteins I (gI), X (gpX), and III (gIII) resulted in MLV vaccines discernibly different from field strains of PRV. 1 Depending on the vaccine, the absence of antibodies against gI, gpX, or gIII made it possible to differentiate between pigs vaccinated with a gene-deleted vaccine and pigs infected with field strains of PRV. In 1988, the first MLV gene-deleted PRV vaccine and its companion differential diagnostic enzyme-linked immunosorbent assay (ELISA) were licensed in the USA. 4 Since 1988, several other differential ELISAs have been developed for PRV vaccines that contain natural gene mutations or genetically engineered gene deletions?
The development of gene-deleted vaccines and differential ELISAs has been critical to the prevention and control of pseudorabies. In the USA and elsewhere, the control and eradication of PRV is dependent on the use of efficacious PRV vaccines that also allow for the differentiation of noninfected, vaccinated pigs from infected pigs. 6 In the recent past, differential PRV vaccines were either gI, gpX, or gIII gene deleted. Although efficacious, these vaccines have presented an obstacle to the movement and sale of animals. Producers and veterinarians using differential vaccines and diagnostic laboratories performing differential tests have had to monitor which animals received which vaccine for the proper differential ELISA to be used in testing. Part of the advantage offered by the improvement in PRV vaccine technology has been lost in the increased workload and confusion created by the need for accurate accounting of vaccine use.
A newly developed MLV PRV vaccine has gene deletions of the diagnostic antigens gI and gpX and reduced virulence due to deletions of the thymidine kinase gene and the inverted repeat regions. The deletion a gI/gpX-negative vaccine will not interfere with the There are no other gene-deleted PRV vaccines presently available that are compatible with 2 differential diagnostic tests. The purpose of this research was to determine 1) if pigs vaccinated multiple times with the gI/gpX gene-deleted vaccine would remain seronegative on commercial gI and gpX serologic tests and 2) if pigs previously vaccinated with gI or gpX gene-deleted vaccines currently available could be revaccinated with the gI/gpX-negative vaccine and still remain seronegative on the companion serologic assays.
Materials and methods
Animals and housing. Seventy-two pigs, 5-6 wk of age, were obtained from a pseudorabies-free herd and were confirmed to be serologically negative for PRV antibodies on the screening ELISAa at the time they were placed in isolation facilities.
Virus. The PRV strain used in the challenge experiment was the pneumotropic strain VDL 4892. 2 Madin-Darby bovine kidney (MDBK) cells were grown in a 162-cm 2 flask b containing minimum essential medium c supplemented with 1,000 µg/ml of amphotericin B, d 50 µg/ml of gentamicin sulfate, e and 5% fetal calf serum. f The flask was inoculated with VDL 4892 when the MDBK cell monolayer was 80-90% confluent. The virus was grown for 48 hr and then harvested by freezing and thawing the flask 2 times and centrifuging at 1,400 x g. The virus containing supernatant was stored at -70 C.
Challenge virus was titrated at the time pigs were challenged. Tenfold dilutions of the virus solution were made. Fifty microliters of each virus dilution and 150 µ1 of MDBK cells were added to 8 wells of a microtiter plate, g incubated Table 2 . PRV vaccination and serology protocols for swine. letion of the gene encoding the gI antigen and vaccine D k is an MLV vaccine with a deletion of the gene encoding the gpX antigen.
Serology. Serum samples were tested with commercially available PRV ELISA kits (Table 1) : a screen assay designed for use in nonvaccinated pigs, a blocking gpX assay 1 for pigs vaccinated with vaccines A or D, a blocking gI assay m for pigs vaccinated with vaccines A, B, or C, and an indirect gI assay n for pigs vaccinated with vaccine B. All day 0 serum samples were tested with the screening ELISA to establish that pigs were seronegative for PRV antibodies. Sera collected from pigs vaccinated only with vaccine A were tested on both gI and the gpX assays (Table 2) . Pigs vaccinated with vaccines A and B or A, B, and C were tested on both gI assays. Pigs vaccinated with vaccines A and D were tested on the gpX assay.
Antibody titers were determined using a serum virus neutralization (SVN) test. Sera were heat inactivated for 30 min at 56 C. Twofold dilutions of each serum sample were made in 96-well microtiter plates using minimum essential medium supplemented with 1,000 µg/ml of of amphotericin B and 50 µg/ml of gentamicin sulfate. An equal volume of Shope strain PRV was added to each well at a dose of 100-300 TCID 50 /well. After a 1-hr incubation at room temperature, MDBK cells were added to each well at a sufficient concentration to give a complete monolayer at 48 hr. Plates were incubated at 37 C for 48 hr in a 5% CO 2 atmosphere. The antibody titer was reported as the highest dilution at which there was 100% neutralization of the virus.
Treatment protocols. Pigs were placed into 1 of 4 treatat 37 C in a 5% CO 2 atmosphere for 48 hr, and examined ment groups (Table 2) . Treatment group I received vaccine for typical cytopathic effect. The titer was calculated using A only, and the pigs were challenged with a l-ml dose (4.7 the Kärber method. 8 x 10 6 TCID 50 /ml) of PRV VDL 4892 on day 98. The virus
Vaccines. Vaccine A h is an MLV vaccine with deletions was given intranasally using a 3-cc syringe fitted with a 16of the genes encoding the diagnostic antigens gI and gpX gauge needle that had been shortened to 5 mm. Latex tubing o (Table l) , vaccines B i and G are MLV vaccines with a de-1.6 mm x 0.8 mm was cut into a 35-mm length and placed over the cut needle to ensure virus deposition in the nasal cavity. Blood was collected from pigs in group I on days 20, 29, 42, 72, 81, 98, and 112 . Pigs in the remaining 3 treatment groups received vaccine A and other commercially available gene-deleted PRV vaccines. Blood was collected from pigs in group II on days 9, 73, and 82 and from pigs in groups III and IV on days 22 and 37.
Results
Swine that received only vaccine A remained seronegative on both gI assays and the gpX assay until the time of challenge. All pigs were seronegative on the SVN test on day 0 and had titers of ≥ 64 by day 29 postvaccination. The pigs remained clinically normal throughout the 14-day observation period postchallenge. By day 14 postchallenge, the pigs were seropositive on all 3 differential tests and showed a rise in antibody titer to ≥ 256 on the SVN test. The pigs in group II remained seronegative on the blocking gI assay and had SVN titers of 1:4-1:16 by day 82 postvaccination. Twenty-three of the group III pigs and 24 of the group IV pigs were monitored to the end of the study. Three pigs were lost to the study and could not be evaluated: 2 died from causes unrelated to the vaccination, and 1 lost an ear tag. The pigs in group III remained seronegative on both gI assays throughout the study, and the pigs in group IV remained seronegative on the gpX assay. The SVN antibody titers were 52 on day 22 and 1:4-1:32 on day 37 postvaccination.
Discussion
Pigs vaccinated multiple times with large doses of vaccine A were serologically negative on all 3 differential tests. Unusually large vaccine doses, excessive numbers of vaccinations, and nonstandard routes of vaccination did not cause false-positive serologic reactions. All animals seroconverted following challenge with PRV. These results indicate that swine vaccinated multiple times with vaccine A will remain seronegative on differential tests in the absence of a source of gI or gpX, such as through exposure to PRV, or from gI-or gpX-containing vaccines.
Vaccine A was evaluated for its potential to cause false-positive reactions when used in combination with 1 gpX and 2 gI gene-deleted vaccines that are currently licensed in the USA. Animals vaccinated with a gpX gene-deleted vaccine remained seronegative on the gpX assay, and the pigs vaccinated with 1 or both gI genedeleted vaccines remained seronegative on the gI assays following vaccination with vaccine A. These results indicate that vaccine A can be used in herds already vaccinated with one of the other vaccines without noninfected pigs seroconverting on the companion differential test.
The fact that vaccine A has 2 diagnostic glycopro-teins deleted offers a significant economic advantage to producers and veterinarians. Serum from pigs vaccinated solely with vaccine A can be tested on either the gpX assay or gI assay. If a serum sample tests suspect or positive on 1 of these tests, the test result can be confirmed on the other test using the same serum sample. At the very least, this offers a savings in time and expense incurred in obtaining another sample. From the perspective of disease eradication and control, the availability of 2 tests based on different "indicators" (i.e., gI vs. gpX antibodies) means that singleton reactors from pseudorabies herd tests can be quickly and easily retested with a greater likelihood of arriving at the correct diagnosis. The use of a vaccine in which there are gene deletions of 2 diagnostic antigens also has the advantage of allowing a producer to sell pigs to producers that are using a PRV vaccine containing a single diagnostic deletion, either gI or gpX. In this instance, the buyer can purchase these pigs and continue to use the singledeletion vaccine and testing system already in place.
The availability of vaccine A in the market place will alleviate many of the problems associated with serologic testing of pigs when a producer wishes to change from 1 diagnostic glycoprotein test system to the other. Prior to the development of this vaccine, there was no alternative vaccine available that could be used in a herd already vaccinated with a gI or gpX gene-deleted vaccine without causing some diagnostic confusion during the transition. Vaccine A allows a producer to make the transition without having to utilize 2 different vaccines on the farm at the same time, thus reducing the chances of inadvertently vaccinating pigs with the wrong PRV vaccine.
Accurate serologic evaluation of pigs vaccinated with differential vaccines depends on producers having good vaccination records and a means of readily identifying vaccinated pigs. Problems will continue to arise because of incomplete or inaccurate records, misidentification of animals, or mislabeling of samples. However, the use of this vaccine should reduce the problems associated with the use of multiple PRV vaccines in swine. 
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